Cargando…
Breakthrough treatment choice for Acute Myeloid Leukemia in pediatric and adult patients: Revumenib, an oral selective inhibitor of KMTA2Ar
Autores principales: | Fareed, Areeba, Inam, Nimrah, Faraz, Fatima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272631/ https://www.ncbi.nlm.nih.gov/pubmed/37333047 http://dx.doi.org/10.1177/20363613231183785 |
Ejemplares similares
-
P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE
por: Rubnitz, Jeffrey, et al.
Publicado: (2023) -
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
por: Issa, Ghayas C., et al.
Publicado: (2023) -
1150. Breakthrough Invasive Fungal Disease (IFD) in Patients with Acute Myeloid Leukemia (AML)
por: Wasylyshyn, Anastasia, et al.
Publicado: (2020) -
The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
por: Saydam, Guray, et al.
Publicado: (2022) -
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
por: Elgamal, Ola A., et al.
Publicado: (2020)